News

ABX-CRO goes SNMMI 2023

Once again we will be attending the premier event for education, science, research and networking in nuclear medicine and molecular imaging - SNMMI 2023 - you will find us in Chicago, Illinois, June 24-27, Booth #3082. We have been an almost annual attendee of this...

read more

Andreas Fintelmann visiting iSRS23

Our General Manager Andreas Fintelmann is heading to Honolulu in May to attend the 25th iSRS conference. From 22-25.5. there will be an outstanding collection of plenaries and workshops. A great opportunity to reactivate old connections and make new ones while in the...

read more

ABX-CRO at TRP 2022

Meet ABX-CRO executives at the TRP 2022 Annual Meeting December 6-8 | Amsterdam. Join us for our presentation about taking Radipharmaceuticals to their next evulitionary level.

read more

ABX-CRO at SNMMI 2022

Meet ABX-CRO executives at the SNMMI 2022 Annual Meeting June 11-14 | Vancouver, BC, at booth no. # 649. Celebrate with us our inauguration of our Boston-based US branch ABX-CRO Inc., further strengthening our global operations, and see the latest version of QDOSETM,...

read more

New Alliance: DRIVE™-MRT

ABX-CRO (Dresden, Germany), the globally leading full-service CRO for molecular imaging and radiotherapy, ONCODESIGN (ALONC -FR0011766229), a French biopharmaceutical company dedicated to precision medicine, Covalab (Bron, France), a biotechnology company specializing in the development and production of custom antibodies and CheMatech (Dijon, France), the European leader in the design announce their partnership. This strategic collaboration will launch the DRIVE™-MRT (Molecular RadioTherapy) solution. This innovative, premium service offer for therapeutic development is unique in nuclear medicine; it encompasses the full drug discovery process of theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimization, preclinical candidate drug generation and IND, to the design and management of clinical trials.

read more